| Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy MP Keizer, D Wouters, LJ Schlapbach, TW Kuijpers Molecular immunology 61 (2), 174-184, 2014 | 51 | 2014 |
| TFPI inhibits lectin pathway of complement activation by direct interaction with MASP‐2 MP Keizer, RB Pouw, AM Kamp, S Patiwael, G Marsman, MH Hart, ... European journal of immunology 45 (2), 544-550, 2015 | 34 | 2015 |
| MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis AM Barendregt, SR Veldkamp, PCE Hissink Muller, A van de Geer, ... Rheumatology 59 (9), 2392-2401, 2020 | 16 | 2020 |
| Plasma-derived mannose-binding lectin shows a direct interaction with C1-inhibitor MP Keizer, AM Kamp, N Brouwer, MD van de Wetering, D Wouters, ... Molecular immunology 58 (2), 187-193, 2014 | 13 | 2014 |
| Substitution of mannan-binding lectin (MBL)-deficient serum with recombinant MBL results in the formation of new MBL/MBL-associated serine protease complexes MP Keizer, A Kamp, G Van Mierlo, TW Kuijpers, D Wouters Frontiers in immunology 9, 1406, 2018 | 8 | 2018 |
| The high prevalence of functional complement defects induced by chemotherapy MP Keizer, AM Kamp, C Aarts, J Geisler, HN Caron, MD van de Wetering, ... Frontiers in immunology 7, 420, 2016 | 8 | 2016 |
| Asparaginase inhibits the lectin pathway of complement activation MP Keizer, C Aarts, AM Kamp, HN Caron, MD van de Wetering, ... Molecular immunology 93, 189-192, 2018 | 6 | 2018 |
| The lectin pathway is inhibited by an anti-coagulant protease inhibitor acting on MASP-2 D Wouters, M Keizer, M Hart, R Pouw, A Wolbink, T Kuijpers, D Hamann, ... Molecular Immunology 14 (48), 1687, 2011 | 1 | 2011 |
| Mischa P. Keizer1, 2*, Angela Kamp1, Gerard van Mierlo1, Taco W. Kuijpers2, 3 and Diana Wouters1 TE Mollnes, T Fujita, P Gál, MP Keizer, MP Keizer, A Kamp, G van Mierlo, ... Frontiers in Immunology 9 (1406), 1, 2018 | | 2018 |
| Complement activation defects in pediatric oncology patients: hidden factors contributing to the increased risk of infection MP Keizer Faculty of Medicine, AMC Amsterdam, 2018 | | 2018 |
| The High Prevalence of Functional Complement Defects Induced by Chemotherapy M van de Wetering, M Keizer, A Kamp, C Aarts, G Judy, D Wouters, ... PEDIATRIC BLOOD & CANCER 63, S292-S292, 2016 | | 2016 |
| Low functionality of plasma-derived MBL upon substitution in MBL-deficient patients possibly explained by interaction with C1-inh M Keizer, N Brouwer, A Kamp, G van Mierlo, D Wouters, T Kuijpers Tijdschrift voor Kindergeneeskunde 81, 59-59, 2013 | | 2013 |
| Plasma-derived MBL shows direct interaction with C1-inhibitor M Keizer, N Brouwer, A Kamp, M van de Wetering, D Wouters, T Kuijpers Molecular Immunology 3 (56), 262, 2013 | | 2013 |
| Complement activation defects in pediatric oncology patients: hidden factors contributing to M Keizer | | |
Richard PouwPhD, Group Leader at Sanquin ResearchVerified email at sanquin.nl
